The assets of Israeli drugmaker Teva Pharmaceutical International (NYSE: TEVA) in the UK, Ireland and Iceland) have attracted interest from bidders including Netherlands-incorporated Mylan (Nasdaq: MYL) and Swiss pharma giant Novartis (NOVN: VX), Bloomberg reports.
Insiders quoted by Bloomberg report that private equity firms Apollo Global Management and Cinven are also weighing up making bids for the business, which could cost $1.5 billion to $2 billion.
It is understood that the European Commission would prefer the assets to go to a buyer with experience in Europe’s generics market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze